combining durvalumab & bvac-c to enhance anti-tumor immune responses in recurrent cervical carcinoma
Published 2 months ago • 67 plays • Length 1:08
Download video MP4
Download video MP3
Similar videos
-
0:52
phase i/iia study of bvac-c and durvalumab in hpv-positive recurrent cervical carcinoma
-
0:27
next steps in evaluating durvalumab and bvac-c for hpv-positive cervical cancer
-
0:42
combining cemiplimab and isa101b for the treatment of recurrent/metastatic hpv16 cervical cancer
-
5:20
calla: phase iii study of durvalumab and chemoradiotherapy for cervical cancer
-
1:30
dirva: intratumorally injected durvalumab for cervical cancer
-
2:19
cervical screening - over 25
-
2:25
how common is cervical cancer?
-
0:30
treatment options for recurrent cervical cancer | premal thaker, md, ms | asco22 gyn cancer updates
-
1:01
immunothearpy combo treating advanced cervical cancer | osuccc – james
-
2:33
updates from a phase i clinical trial examining ublituximab in combination with tgr-1202
-
27:49
cervical cancer: risk factors, pathophysiology, symptoms, staging, diagnosis, treatment & prevention
-
2:49
how should locally advanced cervical cancer be treated?
-
44:01
webinar: combination of durvalumab, bevacizumab, tremelimumab & transarterial chemoembolization
-
7:53
pembrolizumab for persistent, recurrent, or metastatic cervical cancer
-
8:25
cervical cancer: osmosis study video
-
2:07
what are the risk factors for cervical cancer? | dana-farber cancer institute
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
8:54
hybrid tx for multilevel disease - hyun bae, md
-
0:42
dr. rischin discusses role of cemiplimab in cervical cancer
Clip.africa.com - Privacy-policy